Eyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on Wednesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) will likely be announcing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.77) per share and revenue of $3.3290 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:30 AM ET.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%.The firm had revenue of $5.33 million during the quarter, compared to analysts’ expectations of $6.82 million. On average, analysts expect Eyepoint Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Eyepoint Pharmaceuticals Stock Up 7.2%

Shares of NASDAQ:EYPT opened at $13.09 on Monday. The business has a 50-day moving average price of $12.84 and a 200-day moving average price of $10.11. The stock has a market cap of $902.25 million, a price-to-earnings ratio of -4.88 and a beta of 1.95. Eyepoint Pharmaceuticals has a 52-week low of $3.91 and a 52-week high of $14.91.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Mizuho set a $28.00 price target on Eyepoint Pharmaceuticals in a research report on Monday, October 20th. HC Wainwright lifted their price target on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Chardan Capital reiterated a “buy” rating and set a $27.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.67.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in EYPT. Rhumbline Advisers increased its position in shares of Eyepoint Pharmaceuticals by 11.0% in the second quarter. Rhumbline Advisers now owns 96,280 shares of the company’s stock valued at $906,000 after buying an additional 9,548 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Eyepoint Pharmaceuticals by 57.8% in the second quarter. American Century Companies Inc. now owns 67,612 shares of the company’s stock worth $636,000 after acquiring an additional 24,752 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Eyepoint Pharmaceuticals by 199.8% in the second quarter. Invesco Ltd. now owns 128,772 shares of the company’s stock worth $1,212,000 after acquiring an additional 85,824 shares during the last quarter. Raymond James Financial Inc. boosted its stake in shares of Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after acquiring an additional 1,177 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Eyepoint Pharmaceuticals by 9.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock worth $63,988,000 after acquiring an additional 600,000 shares during the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.